Table 2.

Recurrence rate and time to recurrence of anti-vascular endothelial growth factor injection in zone 1 and 2 retinopathy of prematurity.

	Zone 1		Zone 2
	Recurrence rate	Time to recurrence (weeks)	Recurrence rate	Time to recurrence (weeks)
Bevacizumab	6% [33]	NA	5% [33] to 10.5% [39]	5.07 [39]
Ranibizumab	49.09% [61]	7.87 [61]	23.56% to [61] to 26% [42]	8.40 [61] to 12.62 [42]
Aflibercept	0% [60] to 81.8% [72]	6 [72]	0% [60] to 54.2% [72]	6 [72]
Conbercept	0% [36] to 28.57% [61]	10.6 [61]	13.31% [61] to 22.9% [36]	5 [36] to 11.4 [61]